Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 7

1.

Cross-reactive human immunodeficiency virus type 1-neutralizing human monoclonal antibody that recognizes a novel conformational epitope on gp41 and lacks reactivity against self-antigens.

Zhang MY, Vu BK, Choudhary A, Lu H, Humbert M, Ong H, Alam M, Ruprecht RM, Quinnan G, Jiang S, Montefiori DC, Mascola JR, Broder CC, Haynes BF, Dimitrov DS.

J Virol. 2008 Jul;82(14):6869-79. doi: 10.1128/JVI.00033-08.

3.

Progress towards the development of a HIV-1 gp41-directed vaccine.

McGaughey GB, Barbato G, Bianchi E, Freidinger RM, Garsky VM, Hurni WM, Joyce JG, Liang X, Miller MD, Pessi A, Shiver JW, Bogusky MJ.

Curr HIV Res. 2004 Apr;2(2):193-204. Review.

PMID:
15078183
4.

The membrane-proximal external region of the human immunodeficiency virus type 1 envelope: dominant site of antibody neutralization and target for vaccine design.

Montero M, van Houten NE, Wang X, Scott JK.

Microbiol Mol Biol Rev. 2008 Mar;72(1):54-84, table of contents. doi: 10.1128/MMBR.00020-07. Review.

5.

Phages and HIV-1: from display to interplay.

Delhalle S, Schmit JC, Chevigné A.

Int J Mol Sci. 2012;13(4):4727-94. doi: 10.3390/ijms13044727. Review.

6.

Influenza virus antigenicity and broadly neutralizing epitopes.

Air GM.

Curr Opin Virol. 2015 Apr;11:113-21. doi: 10.1016/j.coviro.2015.03.006. Review.

Supplemental Content

Support Center